Advertisement

Covaxin News

alt
The most prevalent AESIs in adolescents included new-onset skin and subcutaneous disorders (10.5 per cent) Serious AESI, which included stroke and Guillain-Barre syndrome, was reported in one per cent of individuals Recently, AstraZeneca admitted in the UK High Court about a rare risk of blood clot disorder due to its Covid vaccine
alt
Govt clears Corbevax as Covid-19 booster dose for adults vaccinated with Covaxin, Covishield Health Ministry's approval is based on the recommendations made by the NTG Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.
alt
CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose. People who are 18 years & above & have already taken two doses of either COVISHIELD or COVAXIN can now receive a dose of CORBEVAX. The vaccine can be taken after 6 months of two doses of Covaxin or Covishield vaccines for restricted use in emergency situation.
alt
Germany has cleared the Bharat Biotech’s Covaxin Now, fliers won’t need to show vaccination proof now from June 1 This was also confirmed by German Ambassador Walter J Lindner
alt
Sputnik booster dose has been approved in India. Over 6.5 lakh people who have received Sputnik vaccine will be eligible to take the booster dose. India had earlier approved a third dose of COVID vaccines – Covaxin and Covishield – for adults.
alt
Bharat Biotech has sought nod for conducting booster dose trials of Covaxin for 2-18 age group. So far 2,88,62,660 precaution doses to the eligible beneficiaries.
alt
In India, now even 5-year-old children can be given vaccinated against coronavirus. Corbevax vaccine of Biological E Company has been approved for those between 5 to 12 years of age while Covaxin will be given to children between 6 to 12 years of age. These vaccines are administered in two doses each of which is given at an interval of 28 to 40 days
alt
The Drugs Controller General of India (DCGI) has given a restricted emergency use authorisation to Bharat Biotech's Covaxin for children aged 6-12 years, ANI news agency reported on Tuesday (April 26, 2022).
alt
Covaxin is developed indigenously by the Bharat Biotech India and Japan acknowledged the progress in the ongoing projects in Bangladesh
alt
Covaxin, an indigenous Covid-19 vaccine, is produced by Hyderabad-based Bharat Biotech. "I don`t think that`s a cause for worry at all," MEA spokesperson Arindam Bagchi said.
alt
The Hyderabad based Bharat Biotech`s anti-Covid Vaccine, Covaxin has been suspended by WHO under the Covax facility, announced the UN health body on Saturday, attributing it to deficiencies in manufacturing practices.
alt
Bharat Biotech said there were no issues with its Covid-19 vaccine or its certification. The data available to WHO, indicate the vaccine is effective and no safety concern exists, informed Bharat Biotech.
alt
The WHO said the Bharat Biotech vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption of Covaxin supply. 
alt
Ocugen, Inc is co-developing Bharat Biotech`s Covaxin vaccine candidate for COVID-19 in USA and Canada
alt
DCGI has granted approval under New Drugs and Clinical Trials Rules, 2019. Private hospitals and clinics will be able to purchase these Covid-19 vaccines.
alt
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year Serum Institue of India had submitted application to DCGI seeking regular market approval for Covishiled
alt
An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said.
alt
The Centre said media reports are "not factually correct and do not reflect the correct picture of the available stock of balance and unutilised Covid vaccine doses with Maharashtra". 
alt
The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot, the Bharat Biotech said. 
alt
Based on emerging data, Bharat Biotech believes that a third dose may be beneficial to maintain the highest levels of protection.






Loading...
english news
NEWS ON ONE CLICK